A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies and Expansion Cohort to Oropharyngeal Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies and Expansion Cohort to Oropharyngeal Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Avelumab (Primary) ; Tipapkinogene sovacivec (Primary)
  • Indications Head and neck cancer; Oropharyngeal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 19 Sep 2017 According to a Transgene media release, the first patient has been treated in the trial at the Curie Institute, Paris, France.
    • 19 Sep 2017 Status changed from not yet recruiting to recruiting, according to a Transgene media release.
    • 23 Aug 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top